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Background. A number of well-known acquired and putative inherited etiological factors contribute to the development of venous
leg ulcer (VLU). Aim. In this study we set out to perform a meta-analysis of putative genetic and acquired factors predisposing
to VLU development. Methods. VLU patients (𝑛 = 157) were divided into three subgroups in accordance with their acquired
etiological factors. The frequencies of four genetic factors were determined: the R506Q (Leiden) mutation of the F5 gene, the
G20210A mutation of the F2 (prothrombin) gene, the 2451 A/G SNP of the fibroblast growth factor receptor 2 (FGFR2) 3󸀠 UTR,
and the −308G/A SNP of the tumor necrosis factor 𝛼 (TNFA) promoter. Results.The −308 TNFA SNP exhibited a higher frequency
among VLU patients without known acquired predisposing factor in their history, than among patients with thrombosis or soft
tissue infection in their history (Fisher 𝑃 = 0.0173). Conclusions. This study has demonstrated that the group of VLU patients
is heterogeneous in their genetic predisposing factors. Further large-scale studies are needed to delineate the associations among
genetic and acquired etiological factors with regard to VLU development and to integrate the consequences of the already known
genetic factors to the management of VLU.
1. Introduction
Venous leg ulcer (VLU) is multifactorial disease with well-
known acquired and putative inherited predisposing factors
[1–15]. Besides the characteristic acquired etiological factors,
such as venous insufficiency, obesity, and deep vein thrombo-
sis, case-control studies suggest putative inherited etiological
factors, which may also contribute to the mechanism of
delayed or pathological wound healing and hence to the
development of leg ulcer. A delineation of the genetic suscep-
tibility factors relating to pathological wound healing would
therefore promote a better understanding of the molecular
background of VLU and that could provide opportunities
for developing causative treatment of therapy-resistant forms
[1, 2].
The difficulties involved in such investigations are
increased by the fact that these inherited factors form a
complex multifactorial genetic background which does not
follow the rules of Mendelien inheritance. Moreover, each
genetic component contributes differently to the pathogen-
esis of VLU, and assessment of its individual relevance in
the development of the disease is difficult. To investigate
the putative genetic factors and to minimize statistical bias,
we set out to form subgroups of VLU patients which were
homogeneous in their clinical characteristics and to perform
a meta-analysis of four genetic factors within the subgroups.
2. Methods
One hundred and fifty-seven VLU patients with therapy-
resistant nonhealing VLU have been enrolled into the study.
Diabetes and arterial leg ulcer were exclusion criteria. The
female (48.41%) :male (51.59%) ratio was close to 1 : 1. The
average duration of the VLU was 5.84 ± 5.12 years. The
clinically relevant parameters and the clinically homogeneous
subgroups of VLU patients are shown in Table 1.
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Table 1: Clinical characteristics and subgroups of VLU patients.
Clinical characteristics of VLU patients (𝑛 = 157)
Cardiac disease (49.04%, 𝑛 = 77)
Soft tissue infection (47.13%, 𝑛 = 74)
Deep vein thrombosis (29.94%, 𝑛 = 47)
Leg fracture (22.93%, 𝑛 = 36)
Atherosclerosis (20.38%, 𝑛 = 32)
Autoimmune disease (5.10%, 𝑛 = 8)





Group A (𝑛 = 72) − −
Group B (𝑛 = 33) + −
Group C (𝑛 = 52) − +
The frequency and putative interactions of several pre-
viously determined genetic factors (the R506Q [Leiden]
mutation of the F5 gene, the G20210A mutation of the F2
[prothrombin] gene, the 2451 A/G SNP of the FGFR2 3󸀠
UTR, and the −308 G/A SNP of the TNFA promoter) were
earlier assessed in VLU patients [3–6]. The analysis was
based on previous results of genotyping performed by either
PCR-RFLP or PCR TaqMan methods [3–6]. Chi2 tests and
multinomial regression analyses performed by SPSS were
used to determine frequency and genetic interactions.
The investigation was approved by the Internal Review
Board of the University of Szeged. Written informed consent
was obtained from all donors, and the study was conducted
according to the Principles of the Declaration of Helsinki.
3. Results
The R506Q mutation of the F5 gene was detected in het-
erozygous form in 11 patients with an overall frequency of
7.85%, demonstrating a nonsignificant, higher presentation
in group A and group C than in group B (data not shown).
The G20210A mutation of the F2 gene occurred in only 3
patients in heterozygous form; all the others carried the wild-
type allele (data not shown).
The distributions of the rare genotypes (AG and GG) of
the FGFR2 gene polymorphism (2451A/G SNP at the 3󸀠UTR)
were highest in group A (ratio of homozygous mutants
18.84%, rare allele frequency [MAF] = 0.4638) and lowest
in group B (ratio of homozygous rare alleles 8.82%, MAF
= 0.3676, Fisher exact probability test 𝑃 = 0.1227, Odds
ratio 1.4876, CI 0.8804–1.8075; Figure 1). We have previously
reported that the FGFR2 3󸀠UTR 2451A/G polymorphism is
associated with VLU [5], and the present analysis revealed
a similar distribution in the various subgroups of VLU
patients, suggesting an overall susceptibility role for this
polymorphism in the development of the disease.
The−308G/A SNPof the TNFApromoter likewise exhib-
ited the highest frequency in group A (ratio of homozygous
rare alleles 5.8%, MAF = 0.2246), while in groups B and
C homozygous rare genotype was not detected; only the
A B C All A B C All
Group A (𝑛 = 69; without thrombosis,
fracture or soft tissue infection in the medical history)
Group C (𝑛 = 46; with thrombosis
and/or soft tissue infection in the medical history)












TNFA, −308 A/G SNPFGFR2, 2451 A/G SNP
Group B (𝑛 = 34; with fracture, but without thrombosis
or soft tissue infection in the medical history)
∗
𝑃 = 0.0173
Figure 1: Rare allele frequencies of the 2451 A/G SNP of FGFR2
and the −308 A/G SNP of TNFA in the subgroups of VLU patients.
The FGFR2 3󸀠UTR 2451A/G polymorphism exhibited similar dis-
tributions among the subgroups of VLU patients, suggesting an
overall role of susceptibility in the disease development. Our data
also demonstrated that the homozygous rare allele of the−308TNFA
SNP occurred significantly higher among VLU patients without
additional acquired predisposing factors in their history (group A)
than among patients with other known etiological events in their
history (group C; group A versus group C Fisher exact probability
test, 𝑃 = 0.0173).
heterozygous rare genotype was present (group B MAF =
0.1765, group C, MAF = 0.1087; group A versus group B, 𝑃 =
0.2711, odds ratio 1.352, CI 0.6988–2.3189; group A versus
group C, 𝑃 = 0.0173, odds ratio 2.3757, CI 1.0658–4.0073).
It was previously demonstrated that the −308 A/G SNP of the
promoter region of the TNFA gene is a factor predisposing to
VLU development [6, 7]. Our present data indicate that the
homozygous rare genotype of the −308 TNFA SNP occurred
significantly more frequently among VLU patients without
additional acquired predisposing factors in their history
(group A: no thrombosis, fracture, or soft tissue infection)
than among patients with other known etiological events in
their history (group C: patients with previous thrombosis or
soft tissue infection; group A versus group C Fisher exact
probability test 𝑃 = 0.0173; Figure 1). Previously we have
reported that the −308 G/A SNP of the TNFA promoter
is associated with VLU development in obese patients [6].
In the present study, the ratio of obese patients did not
show significant difference within the subgroups of the VLU
patients. In accordance with our previous results, the highest
ratio (38%) was observed in group A, in which the −308
G/A SNP of the TNFA promoter also exhibited the highest
frequency.
Our meta-analysis included an assessment of puta-
tive genetic interactions using the multinomial regression
method. The R506Q mutation of the F5 gene and the
G20210A mutation of the F2 gene were excluded from this
analysis because of their low allele frequency. No interaction
was found between the 2451 A/G SNP of the FGFR2 gene and
the −308 G/A SNP of the TNFA gene. The 2451 A/G SNP of
the FGFR2 gene proved to be a significantly (5-fold) stronger
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Table 2: Putative genetic factors predisposing to VLU development.
Detected genetic abnormality Population Author Journal Year
(1) F5 gene R506Q (Leiden)∗ German Peus et al. J Am Acad Dermatol 1996
(2) F2 gene G20210A∗ Romanian Jebeleanu et al. J Cell Mol Med 2001
(3) F13A gene V34L Italian Gemmati et al. Wound Repair Regen 2004
(4) FGFR2 gene 3󸀠 UTR A2451G∗ Hungarian Nagy et al. J Invest Dermatol 2005
(5) ESRB gene CA repeat D14S1026 UK Ashworth et al. J Steroid BiochemMol Biol 2005
(6) HFE gene C282Y Italian Zamboni et al. J Vasc Surg 2005
(7) TNFA gene promoter −308∗ Australian Wallace et al. J Invest Dermatol 2006
Hungarian Nagy et al. J Invest Dermatol 2007
(8) FPN1 gene promoter −8GG Italian Gemmati et al. J Vasc Surg 2009
(9) MMP12 gene promoter −82AA Italian Gemmati et al. J Vasc Surg 2009
(10) Sex chromosome aberrations Austrian Gattringer et al. Acta Derm Venereol 2010
(47,XXY/48,XXXY karyotype)
∗
The distributions of the genotypes and the allele frequencies of these genetic factors were compared in the present study.
susceptibility factor than the −308 G/A SNP of the TNFA
gene.
4. Discussion
Up to now little is known about the genetic background of
VLU; however there have been several papers published in
this topic. The first report on the genetic backgrounds of
VLU was on the Leiden and the prothrombin gene mutation;
the first findings demonstrated their association with venous
thrombosis and later with postthrombotic leg ulcer develop-
ment [3, 8]. The FGFR2 gene encodes keratinocyte growth
factor receptor involved in the proliferation of keratinocytes
and wound healing, while the TNFA gene encodes a well-
known proinflammatory cytokine. The investigated SNPs of
the FGFR2 and TNFA genes were previously proved to be
associated with VLU [5, 6].
Other genetic factors—not investigated in this study—
have been also reported to be associated with VLU (Table 2).
The V34L SNP of the F13A gene was proved to be associated
with the progression of VLU due to its direct effect on the
activity of F13 [9]. Estrogen is a well-known accelerator of
wound healing by dampening the inflammatory response;
a common variant of its receptor (ESRB) increases the risk
of VLU development [10]. The C282Y SNP of the HFE
gene increases the risk of VLU by affecting iron protective
mechanisms [11]. A DNA-array reported by Gemmati et al.
(2009) revealed that the −82 A/G SNP of the MMP12 and the
−8 G/C SNP of the FPN1 genes are also associated with VLU
[12]. Moreover, chromosomal abnormalities have also been
found in VLU patients with unusual early onset [16].
The aimof this studywas to assess the relevance of already
known genetic factors and their interactions in VLU devel-
opment in clinically homogeneous subgroups of patients.
Deep vein thrombosis, soft tissue infection, and leg fracture
frequently found clinical characteristics amongVLUpatients,
were suitable for the creation of clinically homogeneous
subgroups within our study population. Cardiac disease was
also frequent, but displayed a very similar distribution in
the VLU patient subgroups. Of the four investigated genetic
factors, the 2451 A/G SNP of the FGFR2 gene proved most
relevant.
Our data further emphasize the importance of clinically
homogeneous subgroups of patients for the analysis of puta-
tive genetic factors in order to assess mutual relevance, to cre-
ate hierarchy, and to measure potential interactions. Further
larger-scale studies are needed to assess the contributions of
different putative genetic factors to the variable appearance
of VLU phenotypes. Such analyses could hold the key to
the understanding of VLU development. They might also
serve a crucial role in the development of future causative
treatment strategies through the creation of cost-effective
investigation techniques for routine diagnostic assessment of
putative genetic factors and causative treatment options.
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